It is established by a Chinese scientist, Dr. Charlene Liao, a cutting-edge company that innovates cancer immunotherapy for new targets.
Location: United States, California, Palo Alto
Employees: 11-50
Total raised: $244M
Founded date: 2016
Investors 11
Show more
Funding Rounds 4
| Date | Series | Amount | Investors |
| 06.01.2023 | Series B | $131M | - |
| 30.03.2021 | Series A | $73M | - |
| 18.09.2018 | Series B | $33M | - |
| 06.09.2016 | Series A | $7M | - |
Mentions in press and media 16
| Date | Title | Description |
| 23.04.2024 | Immune Health Supplements market expands to USD 68680 million by 2029 with a CAGR of 6.2% during 2023-2029 | Immune Health Supplements market expands to USD 68680 million by 2029 with a CAGR of 6.2% during 2023-2029 04-23-2024 11:35 AM CET | Advertising, Media Consulting, Marketing Research Press release from: Quants and Trends Immune Health Suppl... |
| 30.03.2023 | Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator | - |
| 06.01.2023 | Immune-Onc Therapeutics Closes $131M Series B | PALO ALTO, CA, Immune-Onc Therapeutics, a private, clinical-stage cancer immunotherapy company, has closed $131 million in Series B financing. >> Click here for more funding data on Immune-Onc Therapeutics >> To export Immun... |
| 14.04.2021 | Immune therapy startup scores $189M | Flagship Pioneering-backed Repertoire Immune Medicines has raised a $189 million Series B from investors including SoftBank's Vision Fund 2. Based in the Boston area, the clinical-stage biotech company is a developer of immune therapies int... |
| 30.03.2021 | Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors | - |
| 30.03.2021 | Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors | Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 finan... |
| 18.03.2021 | Boston Immune Technologies and Therapeutics Raises $10M Series A Financing | Boston Immune Technologies and Therapeutics, Inc. (BITT), a Boston, MA based developer of novel TNF Superfamily antagonist antibodies, completed a $10M Series A/A1 financing. Investors included BeiGene, Ltd., along with undisclosed private ... |
| 17.03.2021 | Boston Immune Technologies and Therapeutics Raises $10M Series A Financing | BOSTON--(BUSINESS WIRE)--Mar 17, 2021-- Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel TNF Superfamily antagonist antibodies, announced today that the company has completed $10 M Series A/A1 pr... |
| 19.09.2018 | Immune-Onc Therapeutics Raises More Than $33M in Series B Funding | Immune-Onc Therapeutics, Inc., a Palo Alto, Calif.-based cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments, raised more than $33m in Series B funding. Backers included Northern Light Ventur... |
| 18.09.2018 | Immune-Onc raises $33M in Series B funding round for immunotherapy pipeline | The firm announced in September 2016 the closing of a $7 million Series A funding round, in which major investors included Fame Mount Limited and CLI Ventures. CLI, which has offices in Palo Alto and New York, has invested in companies like... |
Show more